99Z:F:F-MODUS THERAPEUTICS HLDG (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.1305

Change

-0.01 (-8.42)%

Market Cap

USD 5.19M

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide to treat patients with sepsis, septic shock, and severe malaria conditions, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOV:F Novo Nordisk A/S

-0.20 (-0.19%)

USD 474.00B
NOVA:F Novo Nordisk A/S

+0.50 (+0.48%)

USD 471.87B
RGO:F Regeneron Pharmaceuticals Inc

-17.00 (-1.81%)

USD 104.28B
CSJA:F CSL LTD SPON.ADR 2

N/A

USD 85.13B
CSJ:F CSL Limited

N/A

USD 85.06B
DUL:F Alnylam Pharmaceuticals Inc

-1.30 (-0.53%)

USD 31.84B
UNC0:F UCB S.A. UNSP.ADR 1/2

+1.00 (+1.24%)

USD 30.73B
1AEA:F argenx SE

-6.00 (-1.22%)

USD 29.94B
1AE:F Argen-X

+2.60 (+0.53%)

USD 29.76B
22UA:F BioNTech SE

+0.40 (+0.36%)

USD 25.58B

ETFs Containing 99Z:F

DWAS Invesco DWA SmallCap Mome.. 2.09 % 0.60 %

+1.66 (+1.54%)

USD 0.98B
DWMC 1.80 % 0.00 %

N/A

N/A
FNY First Trust Mid Cap Growt.. 0.90 % 0.70 %

+1.02 (+1.54%)

USD 0.36B
FNX First Trust Mid Cap Core .. 0.44 % 0.62 %

+1.67 (+1.54%)

USD 1.24B
BBSC JPMorgan BetaBuilders U.S.. 0.42 % 0.00 %

+1.01 (+1.54%)

USD 0.53B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.37% 54% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.37% 53% F 29% F
Trailing 12 Months  
Capital Gain -33.92% 35% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.92% 35% F 15% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -16.28% N/A N/A 14% F
Dividend Return -16.28% N/A N/A 13% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.63% N/A N/A 56% F
Risk Adjusted Return -68.86% N/A N/A 16% F
Market Capitalization 5.19M 13% F 8% B-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.